ABBOTT PARK, Ill. and WALTHAM, Mass., Nov. 17 /PRNewswire-FirstCall/ -- Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott’s ARCHITECT immunochemistry instrument platform, specifically the company’s i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine’s intellectual property related to galectin-3. Financial terms were not disclosed.
Galectin-3 is a protein that plays an integral role in the biological functions related to the initiation and progression of cardiac fibrosis and scarring which is a leading cause of heart failure (HF). Several studies have shown that galectin-3 may provide valuable insight about heart failure and its underlying disease processes.
About Abbott Diagnostics
Abbott Diagnostics is a global leader in in vitro diagnostics, with expertise in cardiac, metabolic and renal testing. Abbott’s comprehensive portfolio of cardiac tests includes biomarkers that help thousands of labs and doctors around the world to diagnose and assess heart failure and myocardial infarction. With more than 69,000 institutional customers in more than 100 countries, Abbott’s diagnostic products offer customers quick processing of results, automation, convenience, cost effectiveness and flexibility.
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.
ARCHITECT, i1000SR and i2000SR are trademarks of Abbott Laboratories.
CONTACT: Media, Ann Fahey-Widman, +1-847-938-6388, Financial, Tina
Ventura, +1-847-935-9390, both of Abbott; or Chris Fontes of BG Medicine,
+1-781-434-0203
Web site: http://www.abbott.com/
http://www.bg-medicine.com//
